P2176
P3781
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresAn Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsBrivaracetam as add-on Treatment in Adolescents and Adults Suffering From EpilepsyA Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationBrivaracetam Observational StudyClinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: BrivaracetamOpen-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With EpilepsyA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With EpilepsyA Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic SeizuresBrivaracetam Safety and Efficacy Follow-up Study in Subjects With EpilepsyA Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With EpilepsyStudy to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset SeizuresA Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on PadsevonilSafety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic TherapyA Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationBrivaracetam Efficacy and Safety Study in Subjects With Partial Onset SeizuresEffect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset SeizuresEfficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic SeizuresAn Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of BrivaracetamCompassionate Use Program With Brivaracetam for the Treatment of Patients With EpilepsyComparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy VolunteersEvaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With EpilepsyEffect of Brivaracetam in Photosensitive Epileptic SubjectsBrivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and AdultsA Study of Brivaracetam in Subjects With Partial Onset SeizuresFollow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From EpilepsyA Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam TreaA Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit SettingA Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male SubjectsA Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy VolunteersA Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures (2008-08-31)Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures (2007-09-30)Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
P4844
Profile of brivaracetam and its potential in the treatment of epilepsySchedules of Controlled Substances: Placement of Brivaracetam Into Schedule V. Interim final rule, with request for comments[Brivaracetam for add-on treatment in focal epilepsy].Emerging drugs for partial-onset epilepsy: a review of brivaracetamEfficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.Brivaracetam for the treatment of epilepsy.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Brivaracetam: First Global Approval.Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis.Brivaracetam: new compound approved for the treatment of epilepsy.Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.Stereochemistry of the Brivaracetam Diastereoisomers.Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.Brivaracetam augments short-term depression and slows vesicle recycling.Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus.Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresOpen-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsBrivaracetam as add-on Treatment in Adolescents and Adults Suffering From EpilepsyA Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationBrivaracetam Observational StudyClinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: BrivaracetamOpen-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With EpilepsyA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With EpilepsyA Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic SeizuresBrivaracetam Safety and Efficacy Follow-up Study in Subjects With EpilepsyA Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With EpilepsyA Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationBrivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studiesErratum: Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum]Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated TabletBrivaracetam, lumacaftor/ivacaftor, and deoxycholic acidLevetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison
P921
Q61918090-98DBF477-2755-4C97-9DC3-68CB3D13A0F3Q61921414-92BFD2FB-8754-42DA-B5FC-38151809336DQ61921780-D36014A4-D72F-4F1C-8335-251717A3D7BEQ61933754-1B3796E9-90AE-4AE1-87A0-56D711400327Q61980036-76665AF3-DEFD-4910-88ED-C9222B0BB698Q62054554-F8E8A8B2-D238-4124-8344-180E1D5920CEQ62817446-E61B8C76-F479-485A-AFC3-F57714BA054AQ63063265-FDFB471A-6468-4C0C-98AD-FD2A3759AC22Q63334104-6E21F24C-DB0C-4186-AE95-D1B5882806F7Q63404638-998A0565-151A-4817-9E73-7200DEA6198EQ63534392-8D714B4A-D39A-4422-8EFD-559AD66502B1Q63572829-A749D574-4C95-4E38-A9B1-C04FB3F4CE42Q63576611-FA72CEC1-C268-4EE3-B6AD-B203BBC2F2C5Q63578248-76382C1A-3D8D-4A11-82E4-EB803DDCF947Q63598865-74ED9854-4A9C-4247-A91A-D4A611EF3BF8Q63806875-D8A3FC9E-4022-45B9-BE40-D63134AE5CD0Q63812001-758636EF-BAAA-43F8-B13D-91924DE23C90Q63817366-ACB1B17E-9AFA-4359-A908-BBB352A793C7Q63837782-0F8DFA24-AFCD-4AF1-929B-95BE9F08B972Q64043143-8DB65456-E1EE-46A8-8B27-2EF35CD81078Q64220796-A90D8703-DEB9-4030-8092-8917E73CA30EQ64714803-5CDA7D3C-BDE2-4F9C-853C-772C1F16C712Q64796649-90ADCC22-90C7-4B82-9321-99C7F99F07FFQ65369387-958E5B07-E107-4B4D-8393-ED89B051EA13Q65372712-54B37C2D-B46E-4B54-A376-558DFF357174Q65385726-59AF25ED-2061-44D4-BD5C-CDA98C37B5F9Q65475177-32C700EF-597A-46EC-9A7A-F22FF5705116Q66026673-47B6D420-64D0-40C5-837C-20DB94F3825DQ66026675-FC5E21C1-0719-4F22-B004-CBEEACD3E592Q66026696-AFDDA3ED-7A9B-4D3B-87F8-D560AC8DC1CCQ66027435-11604A19-77B9-4722-9200-45710D0466DEQ66028574-867E38F2-5BA3-4EEE-B736-2C74DC1F1D97Q66074984-0EF4518B-9460-4914-9144-2D020A505B3BQ66346317-128A8D59-8262-49F6-BF83-B23382B1DC23Q67126289-83B3B48C-2E54-4805-B340-A52CC9AB945BQ86175647-A82E4025-74FE-4864-8EAF-0807331A6837Q86243544-10AA1DF1-A6F5-4125-A419-B2F3C2084574Q93581174-A4B8AC42-9435-40A2-9826-7B15F059428F
P4844
Q26776317-EAA3B0E1-F1F6-425B-BF0F-44CCA821949DQ28275630-D6234726-F399-43FD-A285-F3494A54698BQ30390285-CE8BE723-222C-488A-B85A-45462EC4612AQ36891212-AF343612-B638-4C67-B385-2DC93BC3651CQ37113376-7CA0DA2A-5599-4A84-801B-945C31FE2089Q38694479-AF1E1B57-AA80-4413-B9B9-46135081052DQ38739649-88F025CE-2AEE-40A6-879B-5DA9B1235281Q38743281-019AE17E-E47D-4CFB-8B53-4F70AD1212FBQ38752407-F9259BCB-E112-4A9E-B5B6-9A8F860AAEC8Q38761155-3B332B5A-61AC-4378-A65F-843AC054D05BQ38851318-2D6EC682-6D4B-499F-901D-BEA662AC13E1Q38922348-EB858BE2-C567-401C-A7F6-A1BBA4DD6E59Q39707630-F67B295D-9598-4E3E-80D6-2A493153374BQ39794501-DD90AD8C-31EA-416D-AB14-85E968B3F164Q39899497-238F563D-4171-4C5C-ABDA-C14ABD65C027Q40134330-EA65572C-3455-4218-9683-EFDE7EE3661CQ47853821-70386B2B-C509-4A25-97C3-51821E3584E0Q48071615-73657252-3519-47DE-ADCA-9F16F01153A8Q53073031-C7A70D22-AC2B-4DFA-BAC6-021F42E77DE1Q61918090-2E9E4A6D-E71C-43F4-A7EB-E08F6A7F7807Q61921780-FDA1D19B-5656-41A7-B3B3-F4741D8400A6Q61933754-5AA70D9D-C32D-493B-AF23-9506308A0A8BQ61980036-BBF49628-4A9A-403D-B7A3-64F66639ED78Q62054554-82B833C9-B773-427F-AB2A-DDED4C096DBCQ62817446-7FFAA367-F2B7-4D0D-926A-E55E1C6543BCQ63063265-F410FF3D-55B5-4BEA-9AB0-81768D39CB46Q63334104-902D25DE-6395-44E0-B68A-496241BD840CQ63404638-D5A1CFFC-1C07-4609-A29B-7EAADB0DE1ACQ63534392-D8078D01-B747-4198-B0D2-96FC5383A2E9Q63572829-FB77A1A4-D2E4-4411-BF6F-F8696AC0015CQ63576611-6EBFF4E0-7D1F-43D6-B7F7-4BA1972B04C1Q63812001-B82387B8-4B65-4A97-AEAC-FA99282AC16DQ86904895-EBDB46B1-F231-4BA2-8E4F-117AADD4129AQ86998877-15E0D6BE-1691-4852-910A-720B50837BDBQ87612670-0953DFEE-B303-4768-903C-BE3C7858C29CQ87983757-BA352137-8356-4DB7-906B-C1A762D98A24Q89306051-08818407-53A5-4A10-BB2E-891623718EAD
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Brivaracetam
@de
Brivaracetam
@it
Brivaracetam
@nl
Brivaracetam
@sh
Brivaracetam
@sr
Brivaracetam
@vi
brivaracetam
@en
brivaracetam
@fr
briwaracetam
@pl
بريفاراسيتام
@ar
type
label
Brivaracetam
@de
Brivaracetam
@it
Brivaracetam
@nl
Brivaracetam
@sh
Brivaracetam
@sr
Brivaracetam
@vi
brivaracetam
@en
brivaracetam
@fr
briwaracetam
@pl
بريفاراسيتام
@ar
altLabel
2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
@en
Brivaracetam
@en
UCB 34714
@en
UCB-34714
@en
UCB34714
@en
compound 83α
@en
prefLabel
Brivaracetam
@de
Brivaracetam
@it
Brivaracetam
@nl
Brivaracetam
@sh
Brivaracetam
@sr
Brivaracetam
@vi
brivaracetam
@en
brivaracetam
@fr
briwaracetam
@pl
بريفاراسيتام
@ar
P486
P592
P6366
P646
P661
P662
P683
P117
P2017
CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
P2067
212.152478
P2115
N0000192566
P2175
P231
357336-20-0